{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:12:35Z","timestamp":1790035955545,"version":"4.0.1"},"reference-count":57,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher Education Republic of Poland","award":["dec. MNiSW-DS-6002-4693-23\/WA\/12"],"award-info":[{"award-number":["dec. MNiSW-DS-6002-4693-23\/WA\/12"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Late-onset Alzheimer\u2019s disease (AD) is clinically characterized by a progressive decline of memory and other cognitive functions leading to the loss of the ability to perform everyday activities. Only a few drugs have been approved to treat AD dementia over the past century since the first AD patient was diagnosed. Drugs increasing the availability of neurotransmitters at synapses in the brain are used clinically in the treatment of AD dementia, and cholinesterase inhibitors (ChEIs) are the mainstay of the therapy. A detrimental effect on cognitive function has been reported in patients with pharmacological inhibition of acetylcholinesterase (AChE) by ChEIs and reduced butyrylcholinesterase (BChE) activity due to the single nucleotide polymorphisms. The BChE K-variant (rs1803274), the most common genetic variant of the BCHE gene, was thought to reduce enzyme activity reflecting the lower clinical response to rivastigmine in AD patients. During ChEIs therapy, patients carrying reduced-activity BChE do not present such improved attention like patients with the wild-type enzyme. On the other hand, alterations in the BCHE gene causing enzyme activity reduction may delay AD onset in patients at risk by preserving the level of cortical acetylcholine (ACh). Based on our previous results, we conclude that SNPs localized outside of the coding sequence, in 5\u2019UTR (rs1126680) and\/or intron 2 (rs55781031) of the BCHE gene, but not solely K-variant alteration (p.A539T) itself, are responsible for reduced enzyme activity. Therefore, we suspect that not BChE-K itself, but these coexisting SNPs (rs1126680 and rs55781031), could be associated with deleterious changes in cognitive decline in patients treated with ChEIs. Based on the results, we suggest that SNPs (rs1126680) and\/or (rs55781031) genotyping should be performed to identify subjects at risk for lowered efficacy ChEIs therapy, and such patients should be treated with a lower rivastigmine dosage. Finally, our sequence analysis of the N-terminal end of N-BChE revealed evolutionarily conserved amino acid residues that can be involved in disulfide bond formation and anchoring of N-BChE in the cell membrane.<\/jats:p>","DOI":"10.3390\/biom9100592","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T11:25:57Z","timestamp":1570620357000},"page":"592","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer\u2019s Disease\u2014Could BCHE Genotyping Be Helpful in Alzheimer\u2019s Therapy?"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-6486","authenticated-orcid":false,"given":"Jacek","family":"Jasiecki","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy with Subfaculty of Laboratory Medicine, Medical University of Gda\u0144sk, 80-416 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Was\u0105g","sequence":"additional","affiliation":[{"name":"Department of Biology and Medical Genetics, Medical University of Gda\u0144sk, 80-211 Gda\u0144sk, Poland"},{"name":"Laboratory of Clinical Genetics, University Clinical Centre, 80-952 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer\u2019s disease","volume":"308","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"ref_2","first-page":"a006189","article-title":"Neuropathological Alterations in Alzheimer Disease","volume":"1","author":"Frosch","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00692056","article-title":"Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia","volume":"37","author":"Ball","year":"1977","journal-title":"Acta Neuropathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","article-title":"Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer\u2019s disease","volume":"344","author":"West","year":"1994","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005072-199710000-00002","article-title":"Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease","volume":"56","author":"Hyman","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer\u2019s disease and senile dementia: Loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1995.03520410048025","article-title":"Age-Specific Incidence of Alzheimer\u2019s Disease in a Community Population","volume":"273","author":"Hebert","year":"1995","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrneurol.2013.32","article-title":"Correction: Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer Disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/brain\/99.3.459","article-title":"Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies","volume":"99","author":"Bowen","year":"1976","journal-title":"Brain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: A review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM198611133152001","article-title":"Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type","volume":"315","author":"Summers","year":"1986","journal-title":"New Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/nbdi.2001.0462","article-title":"Widely Spread Butyrylcholinesterase Can Hydrolyze Acetylcholine in the Normal and Alzheimer Brain","volume":"9","author":"Mesulam","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuint.2012.06.016","article-title":"Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene","volume":"61","author":"Johnson","year":"2012","journal-title":"Neurochem. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2014.11.011","article-title":"Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses","volume":"148","author":"Lockridge","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0306-4522(01)00613-3","article-title":"Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine","volume":"110","author":"Mesulam","year":"2002","journal-title":"Neuroscience"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1046\/j.1471-4159.2000.751320.x","article-title":"Abundant Tissue Butyrylcholinesterase and Its Possible Function in the Acetylcholinesterase Knockout Mouse","volume":"75","author":"Li","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z","article-title":"Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation","volume":"393","author":"Darvesh","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cne.10751","article-title":"Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus","volume":"463","author":"Darvesh","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ana.410360506","article-title":"Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia","volume":"36","author":"Mesulam","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002093-199501002-00005","article-title":"Cholinesterases and the Pathology of Alzheimer Disease","volume":"9","author":"Geula","year":"1995","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0006-8993(94)91852-X","article-title":"Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer\u2019s disease patients","volume":"640","author":"Bouras","year":"1994","journal-title":"Brain Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"27265","DOI":"10.1074\/jbc.M110.113647","article-title":"The PRiMA-linked Cholinesterase Tetramers Are Assembled from Homodimers","volume":"285","author":"Chen","year":"2010","journal-title":"J. Boil. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"Lane","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003495-200161010-00005","article-title":"Cholinesterase Inhibitors for Alzheimer\u2019s Disease","volume":"61","author":"Grutzendler","year":"2001","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1570159X14666151208112754","article-title":"Current Treatment Options for Alzheimer\u2019s Disease and Parkinson\u2019s Disease Dementia","volume":"14","author":"Szeto","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/alzrt229","article-title":"Rivastigmine in moderately severe-to-severe Alzheimer\u2019s disease: Severe Impairment Battery factor analysis","volume":"5","author":"Ferris","year":"2013","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase Inhibitors: Pharmacology and Toxicology","volume":"11","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/156720510790274455","article-title":"Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimers Disease: A Review of Recent Clinical Studies","volume":"7","author":"Soininen","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine\u2014A novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17170","DOI":"10.1074\/jbc.M109.004952","article-title":"The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology","volume":"284","author":"Podoly","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1046\/j.1471-4159.2000.740869.x","article-title":"The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme","volume":"74","author":"Altamirano","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cbi.2016.04.030","article-title":"Activity and polymorphisms of butyrylcholinesterase in a Polish population","volume":"259","author":"Jasiecki","year":"2016","journal-title":"Chem. Interactions"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cbi.2019.05.007","article-title":"Haplotypes of butyrylcholinesterase K-variant and their influence on the enzyme activity","volume":"307","author":"Jasiecki","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.0602922103","article-title":"Butyrylcholinesterase attenuates amyloid fibril formation in vitro","volume":"103","author":"Diamant","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/hmg\/6.11.1933","article-title":"Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer\u2019s disease","volume":"6","author":"Lehmann","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s004390000277","article-title":"Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer\u2019s disease","volume":"106","author":"Lehmann","year":"2000","journal-title":"Hum. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/hmg\/7.5.937","article-title":"No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer\u2019s disease","volume":"7","author":"Singleton","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1096-8628(20000403)96:2<167::AID-AJMG8>3.0.CO;2-0","article-title":"No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese","volume":"96","author":"Lee","year":"2000","journal-title":"Am. J. Med Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.12659\/MSM.892982","article-title":"Butyrylcholinesterase K Variant and Alzheimer\u2019s Disease Risk: A Meta-Analysis","volume":"21","author":"Wang","year":"2015","journal-title":"Med Sci. Monit."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/mp.2013.19","article-title":"APOE and BCHE as modulators of cerebral amyloid deposition: A florbetapir PET genome-wide association study","volume":"19","author":"Ramanan","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1038\/s41598-019-41578-3","article-title":"Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer\u2019s disease","volume":"9","author":"Jasiecki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00008571-200304000-00008","article-title":"Regulation of attention and response to therapy in dementia by butyrylcholinesterase","volume":"13","author":"Saxby","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.fpc.0000220573.05714.ac","article-title":"Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer\u2019s disease","volume":"16","author":"Blesa","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000366198","article-title":"Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer\u2019s Disease","volume":"73","author":"Han","year":"2015","journal-title":"Eur. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-160562","article-title":"Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment","volume":"56","author":"Sokolow","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1471-4159.2006.04347.x","article-title":"Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity","volume":"100","author":"Hartmann","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajmg.b.30846","article-title":"Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer\u2019s disease and relationships with response to treatment with Donepezil and Rivastigmine","volume":"150","author":"Scacchi","year":"2009","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"29740","DOI":"10.1074\/jbc.M402752200","article-title":"Combinatorial Complexity of 5\u2032 Alternative Acetylcholinesterase Transcripts and Protein Products","volume":"279","author":"Meshorer","year":"2004","journal-title":"J. Boil. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/jmbi.1999.3091","article-title":"Protein secondary structure prediction based on position-specific scoring matrices","volume":"292","author":"Jones","year":"1999","journal-title":"J. Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"W402","DOI":"10.1093\/nar\/gkz297","article-title":"The PSIPRED Protein Analysis Workbench: 20 years on","volume":"47","author":"Jones","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"W177","DOI":"10.1093\/nar\/gkl266","article-title":"DISULFIND: A disulfide bonding state and cysteine connectivity prediction server","volume":"34","author":"Ceroni","year":"2006","journal-title":"Nucleic Acids Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/10\/592\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:28:45Z","timestamp":1760189325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/10\/592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["biom9100592"],"URL":"https:\/\/doi.org\/10.3390\/biom9100592","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]}}}